209 results on '"Ramió-Torrentà L"'
Search Results
2. Consensus statement of the Spanish Society of Neurology on the treatment of multiple sclerosis and holistic patient management in 2023
3. Consensus statement on the use of alemtuzumab in daily clinical practice in Spain
4. Consenso de expertos sobre el uso de alemtuzumab en la práctica clínica diaria en España
5. Gadolinium-enhanced brain lesions in multiple sclerosis relapse
6. Obesity status and obesity-associated gut dysbiosis effects on hypothalamic structural covariance
7. A guide to treating gait impairment with prolonged-release fampridine (Fampyra®) in patients with multiple sclerosis
8. Guía de tratamiento del deterioro de la marcha con fampridina de liberación prolongada (Fampyra®) en pacientes con esclerosis múltiple
9. Neuroinflammation in obesity: circulating lipopolysaccharide-binding protein associates with brain structure and cognitive performance
10. Four-year safety and effectiveness data from patients with multiple sclerosis treated with fingolimod: The Spanish GILENYA registry
11. Neuroinflammation in obesity: circulating lipopolysaccharidebinding protein associates with brain structure and cognitive performance
12. Caudovirales bacteriophages are associated with improved executive function and memory in flies, mice, and humans
13. CADASIL: arteriopatía cerebral autonómica dominante con infartos subcorticales y leucoencefalopatía
14. Obesity status and obesity-associated gut dysbiosis effects on hypothalamic structural covariance
15. Direct costs of relapses in patients with relapsing-remitting multiple sclerosis
16. 13th Post-ECTRIMS Meeting: review of the new developments presented at the 2020 ECTRIMS Congress (I)
17. Subjects with detectable Saccharomyces cerevisiae in the gut microbiota show deficits in attention and executive function
18. PND22 Discover Study, First Analysis Specific for Secondary Progressive Multiple Sclerosis Burden and Cost in Spain: Interim Analysis Results
19. A kindred with cerebellar ataxia and thermoanalgesia
20. Abnormalities in normal appearing tissues in early primary progressive multiple sclerosis and their relation to disability: a tissue specific magnetisation transfer study
21. Evidence for grey matter MTR abnormality in minimally disabled patients with early relapsing-remitting multiple sclerosis
22. Comparison of two high doses of oral methylprednisolone for multiple sclerosis relapses: a pilot, multicentre, randomized, double‐blind, non‐inferiority trial
23. Long-term Efficacy and Safety of Teriflunomide: An Analysis of Pooled Clinical Trials
24. Guía de tratamiento del deterioro de la marcha con fampridina de liberación prolongada (Fampyra®) en pacientes con esclerosis múltiple
25. Cognitive function in obese subjects
26. Cognitive impairment in early stages of multiple sclerosis is associated with high cerebrospinal fluid levels of chitinase 3-like 1 and neurofilament light chain
27. A guide to treating gait impairment with prolonged-release fampridine (Fampyra ® ) in patients with multiple sclerosis
28. Guía de tratamiento del deterioro de la marcha con fampridina de liberación prolongada (Fampyra ® ) en pacientes con esclerosis múltiple
29. Lipid-specific immunoglobulin M bands in cerebrospinal fluid are associated with a reduced risk of developing progressive multifocal leukoencephalopathy during treatment with natalizumab
30. Antibodies to MOG and AQP4 in adults with neuromyelitis optica and suspected limited forms of the disease
31. Effects of diazoxide in multiple sclerosis: A randomized, double-blind phase 2 clinical trial
32. Comparison of two high doses of oral methylprednisolone for multiple sclerosis relapses: a pilot, multicentre, randomized, double‐blind, non‐inferiority trial.
33. Review of the novelties presented at the 29th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) (I)
34. Evaluating the Effects of White Matter Multiple Sclerosis Lesions on the Volume Estimation of 6 Brain Tissue Segmentation Methods
35. Cognitive impairment in early stages of multiple sclerosis is associated with high cerebrospinal fluid levels of chitinase 3‐like 1 and neurofilament light chain.
36. Plasma exchange for acute attacks of CNS demyelination: Predictors of improvement at 6 months.
37. Paroxysmal dystonia and pathological laughter as a first manifestation of multiple sclerosis.
38. Review of the novelties presented at the 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) (I)
39. Review of the novelties presented at the 28th congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) (II),Revisión de las novedades presentadas en el XXVIII Congreso del Comité Europeo para el Tratamiento e Investigación en Esclerosis Múltiple (ECTRIMS) (II)
40. Review of the novelties presented at the 29th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) (I)
41. Compliance of the guidelines of the Spanish Neurology Society in the treatment of patients with multiple sclerosis,Cumplimiento de las guías de la Sociedad Española de Neurología en el tratamiento de los pacientes con esclerosis múltiple
42. Review of the novelties from the 2014 ECTRIMS-ACTRIMS joint congress, presented at the 7th post-ECTRIMS meeting (II),Revisión de las novedades del congreso conjunto ECTRIMS-ACTRIMS 2014, presentadas en la VII Reunión Post-ECTRIMS (II)
43. [Biomarkers in multiple sclerosis]
44. Review of the novelties presented at the 29th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) (II),Revisión de las novedades presentadas en el XXIX Congreso del Comité Europeo para el Tratamiento e Investigación en Esclerosis Múltiple (ECTRIMS) (II)
45. Review of the novelties presented at the 27th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) (II)
46. [Multiple sclerosis epidemiological situation update: pertinence and set-up of a population based registry of new cases in Catalonia]
47. Review of the novelties presented at the 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) (II)
48. A pipeline approach with spatial information for segmenting multiple sclerosis lesions on brain magnetic resonance imaging
49. Lesiones cerebrales captantes de gadolinio en el brote de los pacientes con esclerosis múltiple
50. Soluble Receptor Isoform of IFN-Beta (sIFNAR2) in Multiple Sclerosis Patients and Their Association With the Clinical Response to IFN-Beta Treatment
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.